<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Autism</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Autism</journal-id>
<journal-title-group>
<journal-title>Molecular Autism</journal-title>
</journal-title-group>
<issn pub-type="epub">2040-2392</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29484150</article-id>
<article-id pub-id-type="pmc">5824550</article-id>
<article-id pub-id-type="publisher-id">196</article-id>
<article-id pub-id-type="doi">10.1186/s13229-018-0196-6</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Short Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Insulin receptor sensitization restores neocortical excitation/inhibition balance in a mouse model of autism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lo</surname>
<given-names>Fu-Sun</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Erzurumlu</surname>
<given-names>Reha S.</given-names>
</name>
<address>
<phone>410-706-7401</phone>
<email>rerzurumlu@som.umaryland.edu</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
</contrib>
<aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2175 4264</institution-id><institution-id institution-id-type="GRID">grid.411024.2</institution-id><institution>Department of Anatomy and Neurobiology, </institution><institution>University of Maryland School of Medicine, </institution></institution-wrap>22 Penn Street HSFII-S259, Baltimore, MD 21201 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>22</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>22</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>9</volume>
<elocation-id>13</elocation-id>
<history>
<date date-type="received">
<day>1</day>
<month>9</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>1</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2018</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Background</title>
<p id="Par1">Met receptor tyrosine kinase regulates neurogenesis, differentiation, migration, connectivity, and synaptic plasticity. The human <italic>Met</italic> gene has been identified as a prominent risk factor for autism spectrum disorder (ASD). Met gene-altered mice serve as useful models for mechanistic studies of ASD. Inactivation of <italic>Met</italic> in excitatory cortical neurons in mice (<italic>Emx1</italic><sup><italic>cre</italic></sup><italic>/Met</italic>
<sup><italic>flox</italic></sup> mice) yields a phenotype in which significantly decreased GABA<sub>A</sub> receptor-mediated inhibition shifts the excitation/inhibition (E/I) balance toward excitation in the somatosensory cortex. Further, unlike that seen in wild-type mice, insulin does not increase inhibition in the mutant cortex, suggesting that one of the consequences of kinase inactive <italic>Met</italic> gene could be desensitization of insulin receptors. To test this hypothesis, we investigated the effects of insulin receptor sensitizer, pioglitazone, on inhibition in the somatosensory thalamocortical circuitry.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">We used whole-cell patch clamp electrophysiology and analyzed excitatory and inhibitory responses of cortical layer IV excitatory cells following stimulation of their thalamic input in thalamocortical pathway intact brain slices. We applied insulin alone and insulin + a thiazolidinedione, pioglitazone (PIO), to test the effects of sensitizing insulin receptors on inhibitory responses mediated by GABA<sub>A</sub> receptors in the somatosensory cortex of <italic>Emx1</italic><sup><italic>cre</italic></sup><italic>/Met</italic>
<sup><italic>flox</italic></sup> mice.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">In WT brain slices, application of insulin together with PIO did not enhance the effect of insulin alone. In contrast, PIO application induced a much larger inhibition than that of insulin alone in <italic>Met</italic>-defective cortex. Thus, insulin resistance of GABA<sub>A</sub> receptor-mediated response in <italic>Met</italic> mutant mice may result from desensitized insulin receptors.</p>
</sec>
<sec>
<title>Conclusions</title>
<p id="Par4">Sporadic clinical studies reported improved behavioral symptoms in children with autism following PIO treatment. We show that PIO can aid in normalization of the E/I balance in the primary somatosensory cortex, a potential physiological mechanism underlying the positive effects of PIO treatment.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Met receptor tyrosine kinase</kwd>
<kwd>Barrel cortex</kwd>
<kwd>Homeostatic plasticity</kwd>
<kwd>GABA<sub>A</sub> receptors</kwd>
<kwd>Pioglitazone</kwd>
<kwd>Thalamocortical circuitry</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id>
<institution>National Institutes of Health</institution>
</institution-wrap>
</funding-source>
<award-id>NS092216</award-id>
<principal-award-recipient>
<name>
<surname>Erzurumlu</surname>
<given-names>Reha S.</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par27">Numerous studies have associated <italic>Met</italic> gene as a of a functional risk allele in autism spectrum disorders (ASD) [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>]. The Met receptor tyrosine kinase is a multifunctional receptor with diverse biological roles activating various intracellular signaling pathways. <italic>Met</italic> mutations in mice provide models to investigate cellular and molecular deficits in the nervous system. One such line, <italic>Emx1</italic><sup><italic>cre</italic></sup><italic>/Met</italic>
<sup><italic>flox</italic></sup> mice (from here on referred to as <italic>Met-Emx1</italic> mouse), has kinase-inactive <italic>Met</italic> gene in excitatory neurons of the neocortex, hippocampus, and olfactory bulbs [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. For cortical studies, these mice may be considered as cortex-specific null mutation of <italic>Met</italic>. Previously, we reported that in thalamocortical brain slices from <italic>Met-Emx1</italic> mice the E/I ratio is biased toward excitation in the primary somatosensory cortex due to decreased GABA<sub>A</sub> receptor-mediated inhibition [<xref ref-type="bibr" rid="CR6">6</xref>]. Excitation-inhibition (E/I) balance in neural circuits is a type of homeostatic synaptic plasticity that is notably affected in various neurological and psychiatric conditions [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p>
<p id="Par28">Insulin receptors are abundant in the brain [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], and insulin regulates GABAergic inhibition by increasing the density of GABA<sub>A</sub> receptors, consequently augmenting inhibitory postsynaptic currents [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. In our study, we found that in wild-type (WT, C57BL/6) brain slices insulin enhances GABA<sub>A</sub> receptor-mediated response. In contrast, insulin treatment had no effect on slices from <italic>Emx1</italic><sup><italic>cre</italic></sup><italic>/Met</italic>
<sup><italic>flox</italic></sup> mice [<xref ref-type="bibr" rid="CR6">6</xref>]. To determine whether sensitizing insulin receptors can enhance GABA<sub>A</sub> receptor-mediated response, we tested pioglitazone (PIO) treatment. PIO is a widely used thiazolidinedione that acts as an insulin-sensitizer through activation of the peroxisome proliferator-activated receptor-γ [<xref ref-type="bibr" rid="CR13">13</xref>]. There are two members of the class thiazolidinediones that have been used as insulin sensitizers in treatment of type 2 diabetes: pioglitazone (Actos) and rosiglitazone (Avandia). We have chosen to use PIO because it is the most widely used and rosiglitazone has yielded less-desirable effects. Furthermore, few clinical studies have reported improved symptoms in neurodevelopmental and neurogeriatric conditions following PIO treatment [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR20">20</xref>]. In the future, testing different members of this drug family under in vivo conditions could yield important insights. In WT thalamocortical slices, application of insulin plus PIO did not enhance the effect of insulin alone. However, this treatment induced a much larger inhibition than that of insulin alone in <italic>Met-Emx1</italic> mice. This finding indicates that the insulin resistance of GABA<sub>A</sub> receptor-mediated response in <italic>Met-Emx1</italic> mice mainly results from desensitized insulin receptors.</p>
</sec>
<sec id="Sec2">
<title>Methods</title>
<sec id="Sec3">
<title>Animals</title>
<p id="Par29">The brain slices were derived from <italic>Met-Emx1</italic> mice of both sexes (<italic>n</italic> = 5). We obtained these mice through crossings of the floxed <italic>Met</italic> mouse (<italic>Met-fx</italic>) with the cerebral cortical and hippocampal specific <italic>Emx1-cre</italic> mouse. Our original sources and further details of the mouse lines are detailed in a previous paper [<xref ref-type="bibr" rid="CR6">6</xref>], currently both lines are commercially available (<italic>Met-fx</italic> stock #016974, <italic>Emx1-Cre</italic>, stock #005628, Jackson Laboratory, Bar Harbor, ME). Control brain slices were from mice with <italic>Met-fx</italic> or <italic>Emx1-cre</italic> alleles alone or C57BL/6 (the background of the mutant line) mice (<italic>n</italic> = 5). There were no differences between the three types of control slices. For mouse use, we followed the National Institute of Health Guide for the Care and Use of Laboratory Animals (ISBN:13:978-0-309-15400-0, revised in 2011) and the UMB SOM Animal Use and Care Committee approved our protocol.</p>
</sec>
<sec id="Sec4">
<title>Brain slice preparation</title>
<p id="Par30">Two- to 4-week-old mice were euthanized and their brains removed into cold sucrose supplemented with artificial cerebrospinal fluid (ACSF, in mM: NaHCO<sub>3</sub> 25, glucose 11, sucrose 234, KCl 2.5, NaHPO<sub>4</sub> 1.25, MgSO<sub>4</sub> 10). Next, we cut 350-μm-thick thalamocortical pathway intact brain slices using a vibratome (Campden 7000msz), at an angle of 50–55° from the mid-sagittal plane and 10° from the coronal plane [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. In such slices, the connections from the ventrobasal nucleus of the thalamus (VB) to the primary somatosensory, specifically the whisker representation zone, the barrel cortex, remain intact. We kept the slices in normal ACSF (in mM: NaCl 126, KCl 3.0, NaH<sub>2</sub>PO<sub>4</sub> 1.25, MgSO<sub>4</sub> 1.0, NaHCO<sub>3</sub> 26, glucose 10, CaCl<sub>2</sub> 2, <sc>l</sc>-ascorbic acid 1.3, pH = 7.4) for at least 1 h, at room temperature. We placed the slice containing the thalamocortical pathway in a submerged-type recording chamber (27 L, Warner Ins.), and continuously perfused (&gt; 2 mL/min) with normal ACSF at room temperature. Under these conditions, intra-cortical circuits are inactivated, and the excitatory thalamocortical synapses on layer IV neurons can be isolated [<xref ref-type="bibr" rid="CR23">23</xref>].</p>
</sec>
<sec id="Sec5">
<title>Thalamocortical slice electrophysiology</title>
<p id="Par31">We prepared borosilicate glass (WPI, K150F-4) whole-cell-patch micropipettes by pulling them in three stages with a P-87 horizontal puller (Sutter Instrument Co.). We backfilled the electrodes with a Cs-based intracellular solution (in mM: CsMeSO<sub>3</sub>, 115; NaCl, 10; KCl, 1, MgCl<sub>2</sub>, 4; CaCl<sub>2</sub>, 1; EGTA, 11; HEPES, 20; Na<sub>2</sub>-ATP, 3; Na<sub>2</sub>-GTP, 0.5, pH = 7.25, &gt; 290 mOsm). The electrodes had a tip resistance of 5–9 MΩ. Spiny stellate and star pyramid cells are the excitatory neurons of layer IV barrel cortex. We patched these neurons to form whole-cell configuration. We passed depolarizing current pulses through the patch pipette in current clamp mode to identify the cells by their firing patterns [<xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR26">26</xref>]. For stimulation of the thalamocortical afferents, we used a concentric electrode (FHC, CBFP J50) either inserted in the VB, which can be visualized in slices or in the internal capsule (IC). We passed 0.33 Hz electrical pulses for 0.3 ms duration, 0.33 Hz to evoke postsynaptic responses in both current- and voltage-clamp modes. We acquired the by Axopatch 200B amplifier and an InstruTECH ITC-16 interface unit and stored on a Dell DM061 computer with PULSE (HEKA) software program.</p>
</sec>
<sec id="Sec6">
<title>Isolation of GABA<sub>A</sub> receptor- and AMPA receptor-mediated postsynaptic currents</title>
<p id="Par32">At − 60 mV holding potential, stimulation of the VB elicits an early inward current (excitatory postsynaptic current, EPSC) followed by an outward current (inhibitory postsynaptic current, IPSC). As we move the holding potential toward more negative values, the outward current becomes smaller, and when this current disappears around − 70 mV holding potential, we define this as the GABA<sub>A</sub> receptor reversal potential. In the absence of any NMDA receptor blockade, the remaining inward current is pure AMPA receptor-mediated EPSC. This inward current can be blocked by 10 μM NBQX, but not by 50 μM picrotoxin (PTX). Changing the holding potential toward more positive values decreased the amplitude of the inward current and it disappeared around 0 mV holding potential, which we defined as the reversal potential for glutamate receptors. The resulting outward current could be completely blocked by 50 μM PTX but not by 100 μM DL-APV; thus, it is the isolated GABA<sub>A</sub> receptor-mediated IPSC. We calculated the ratio of AMPA/GABA (E/I) for each neuron by averaging 10 traces of EPSCs and IPSCs induced by maximal stimulation.</p>
</sec>
<sec id="Sec7">
<title>GABA<sub>A</sub> receptor-mediated spontaneous IPSCs (sIPSCs)</title>
<p id="Par33">We recorded spontaneous IPSCs at 0 mV. We measured the averaged amplitude of sIPSCs using MiniAnalysis Software.</p>
</sec>
<sec id="Sec8">
<title>Chemicals</title>
<p id="Par34">Insulin (500 nM), pioglitazone (PIO, 10 μM), an insulin receptor sensitizer, NBQX (10 μM), an AMPA receptor antagonist, DL-APV (100 μM), a NMDA receptor antagonist, and PTX (50 μM), a GABA<sub>A</sub> receptor antagonist were applied as needed. All chemicals are purchased from Sigma-Aldrich Co. (St. Louis, MO).</p>
</sec>
<sec id="Sec9">
<title>Data analysis</title>
<p id="Par35">We used Student’s <italic>t</italic> test to determine significance. All data are expressed by mean ± s.e.m. (standard error of the mean). Box and whisker plots were generated in R studio version 1.1.419.</p>
</sec>
</sec>
<sec id="Sec10">
<title>Results</title>
<sec id="Sec11">
<title>Functional insulin receptors in the barrel cortex of WT mice</title>
<p id="Par36">Previously, we investigated the thalamocortical synaptic transmission in the barrel cortex of various lines of transgenic and WT mice [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. In complete agreement with those studies, layer IV excitatory neurons show adapting discharges (regular spikes, RS) upon membrane depolarization (Fig. <xref ref-type="fig" rid="Fig1">1</xref>a–c). Stimulation of VB induces an excitatory postsynaptic potential-inhibitory postsynaptic potential (EPSP-IPSP) sequence. At membrane potential of − 60 mV, the IPSP just curtails the EPSP but does not hyperpolarize below − 60 mV (Fig. <xref ref-type="fig" rid="Fig1">1</xref>d, upper trace). The IPSP is reversed in polarity at − 80 mV, suggesting that it is mediated by GABA<sub>A</sub> receptor with a reversal potential around − 70 mV (Fig. <xref ref-type="fig" rid="Fig1">1</xref>d, lower trace).<fig id="Fig1"><label>Fig. 1</label><caption><p>Insulin and pioglitazone treatment effects on the E/I ratio in WT brain slices. <bold>a</bold>–<bold>c</bold> Membrane depolarization characteristically leads to regular spiking of layer IV excitatory neurons. This characteristic is evident in control (WT) slices, and after application of insulin (WT I), or insulin + pioglitazone (WT I + P). <bold>d</bold> EPSP-IPSP sequence following VB stimulation. At − 60 mV, the IPSP does not hyperpolarize below − 60 mV (upper trace). The IPSP polarity reverses at − 80 mV, around GABA<sub>A</sub> receptor reversal potential (lower trace). <bold>e</bold> 500 nM insulin application results in an increase of IPSP that hyperpolarized below base line at − 60 mV (upper trace). The IPSP is mediated by GABA<sub>A</sub> receptor, because it reverses at − 80 mV (lower trace). <bold>f</bold> Addition of pioglitazone to insulin application does not lead to any notable change. <bold>g</bold>–<bold>i</bold> Representative records of GABA<sub>A</sub> receptor- and AMPA receptor-mediated currents under control, insulin, and insulin + pioglitazone application conditions. <italic>HP</italic> holding potential. <bold>j</bold> The averaged AMPA/GABA (E/I) ratios under the three conditions. Note that insulin application significantly reduces the E/I ratio; addition of pioglitazone does not change insulin effects alone. <bold>k</bold> Box and whisker plots showing the population distribution</p></caption><graphic id="MO1" xlink:href="13229_2018_196_Fig1_HTML"></graphic></fig></p>
<p id="Par37">In WT thalamocortical slices, application of 500 nM insulin resulted in an increase of IPSP that hyperpolarized below base line at − 60 mV (Fig. <xref ref-type="fig" rid="Fig1">1</xref>e, WT I, upper trace). The IPSP was also mediated by GABA<sub>A</sub> receptor, because it reversed at − 80 mV (Fig. <xref ref-type="fig" rid="Fig1">1</xref>e, lower trace). In order to quantify the changes in E/I ratio, we voltage-clamped each cell to the reversal potential of GABA<sub>A</sub> receptors (around − 70 mV) and AMPA receptors (around 0 mV) so that we could record GABA<sub>A</sub> receptor- and AMPA receptor-mediated currents (1; 25). Figure <xref ref-type="fig" rid="Fig1">1</xref>g, h are representative records. The averaged AMPA/GABA (E/I) ratio for control WT mice was 1.67 ± 0.22 (<italic>n</italic> = 11, Fig. <xref ref-type="fig" rid="Fig1">1</xref>j, k), while insulin significantly (<italic>p</italic> &lt; 0.001) reduced the ratio to 0.79 ± 0.07 (<italic>n</italic> = 7, Fig. <xref ref-type="fig" rid="Fig1">1</xref>j, k). To test whether the effect of insulin can be further enhanced by insulin receptor sensitizer PIO, we applied both 500 nM insulin and 10 μM PIO (I+P) to the in vitro preparation. The results were largely similar to those obtained with insulin application alone (Fig. <xref ref-type="fig" rid="Fig1">1</xref>c, f, i, j, k). The averaged AMPA/GABA ratio was 0.74 ± 0.03 (<italic>n</italic> = 6, Fig. <xref ref-type="fig" rid="Fig1">1</xref>j, k), which is about the same as insulin alone (<italic>p</italic> &gt; 0.53). Thus, PIO did not increase the effect of insulin on GABA<sub>A</sub> receptor-mediated response in WT slices, suggesting that insulin receptors are saturated by 500 nM insulin.</p>
<p id="Par38">To investigate the mechanism underlying insulin-induced increased inhibition, we recorded GABA<sub>A</sub> receptor-mediated spontaneous IPSCs (sIPSCs) as shown in Fig. <xref ref-type="fig" rid="Fig2">2</xref>a–c. The cumulative fraction curves of the amplitude of sIPSCs (Fig. <xref ref-type="fig" rid="Fig2">2</xref>d) show that the amplitude distribution for WT I (medium thickness line) and WT I + P (thick line) is shifted to the right (larger amplitude) than that of no insulin controls (WT, thin line). This indicated that insulin (I) and insulin + PIO (I + P) increased the amplitude of sIPSCs. The difference between WT I and WT I + P curves resulted from the difference in amplitude distribution. WT I + P group had less (12%) larger (&gt; 30 pA) sIPSCs and WT I group had (19%) larger sIPSCs. However, the averaged amplitude of sIPSCs for WT I and WT I + P (Fig. <xref ref-type="fig" rid="Fig2">2</xref>e, f) showed no significant difference (<italic>p</italic> &gt; 0.08), because the averaged amplitude of sIPSCs of WT I was 22.00 ± 0.76 (<italic>n</italic> = 434) pA, while that for WT I + P was 20.22 ± 0.56 (<italic>n</italic> = 319). Both of them were significantly (<italic>p</italic> &gt; 0.001) larger than the WT group (15.64 ± 0.68 pA, <italic>n</italic> = 320).<fig id="Fig2"><label>Fig. 2</label><caption><p>Insulin-induced increased inhibition. <bold>a</bold>–<bold>c</bold> Example records of GABA<sub>A</sub> receptor-mediated sIPSCs. <italic>HP</italic> holding potential. <bold>d</bold> Cumulative fraction curves of the sIPSC amplitudes show that the amplitude distribution for insulin (WT I) and insulin + pioglitazone (WT I + P) are shifted to the right (larger amplitude), indicating that both conditions increase the amplitude of sIPSCs compared to no drug controls. <bold>e</bold> The average amplitude of sIPSCs is higher with either drug application condition compared to the controls, but not different between the two drug application conditions. <bold>f </bold>Box and whisker plots showing the population distribution</p></caption><graphic id="MO2" xlink:href="13229_2018_196_Fig2_HTML"></graphic></fig></p>
</sec>
<sec id="Sec12">
<title>Insulin receptors are desensitized in the barrel cortex of <italic>Met-Emx1</italic> mice</title>
<p id="Par39">Layer IV of barrel cortex excitatory neurons of <italic>Met-EMx1</italic> mice also show regular spiking upon membrane depolarization (Fig. <xref ref-type="fig" rid="Fig3">3</xref>a–c). Stimulation of VB induced mainly an EPSP without a clear cut IPSP in <italic>Me-Emx1</italic> mice (Fig. <xref ref-type="fig" rid="Fig3">3</xref>d). Isolated AMPA receptor- and GABA<sub>A</sub> receptor-mediated currents revealed a relatively smaller IPSC (Fig. <xref ref-type="fig" rid="Fig3">3</xref>g). The averaged AMPA/GABA ratio for <italic>Met-Emx1</italic> mice was 3.53 ± 0.43 (<italic>n</italic> = 8, Fig. <xref ref-type="fig" rid="Fig3">3</xref>j, k), which is significantly (<italic>p</italic> &lt; 0.001) larger than that of the WT mice (1.67 ± 0.22). In contrast to the WT slices, application of insulin (<italic>Met-Emx1</italic> I) did not change the magnitude of GABA<sub>A</sub> receptor-mediated response (Fig. <xref ref-type="fig" rid="Fig3">3</xref>e, h, j, k). The averaged AMPA/GABA ratio was 3.53 ± 0.42 (<italic>n</italic> = 5) that was just the same as without insulin (<italic>p</italic> &gt; 0.99). The failure of insulin effect on inhibition may result from desensitized insulin receptors; thus, we applied PIO together with insulin (<italic>Met</italic> I + P). Representative records (Fig. <xref ref-type="fig" rid="Fig3">3</xref>f, i) demonstrated that addition of PIO increased GABA<sub>A</sub> receptor-mediated inhibition so that the averaged AMPA/GABA ratio was 0.69 ± 0.08 (<italic>n</italic> = 5), which is significantly (<italic>p</italic> &lt; 0.001) smaller than previous groups (Fig. <xref ref-type="fig" rid="Fig3">3</xref>j, k).<fig id="Fig3"><label>Fig. 3</label><caption><p>Insulin and pioglitazone treatment effects on the E/I ratio in <italic>Met-EMx1</italic> brain slices. <bold>a</bold>–<bold>c</bold> Regular spiking of layer IV excitatory neurons in control (<italic>Met-EMx1</italic>) slices, and after application of insulin (<italic>Met-EMx1</italic> I), or insulin + pioglitazone (<italic>Met-EMx1</italic> I + P). <bold>d</bold>, <bold>g</bold> In mutant brain slices, stimulation of VB induced mainly an EPSP without a clear cut IPSP. Isolated AMPA receptor- and GABA<sub>A</sub> receptor-mediated currents reveal small IPSC. <bold>e</bold>, <bold>h</bold> Application of insulin (<italic>Met-EMx1</italic> I) did not change the magnitude of GABA<sub>A</sub> receptor-mediated response. <bold>f</bold>, <bold>i</bold> Addition of pioglitazone to insulin application dramatically increased GABA<sub>A</sub> receptor-mediated inhibition. <bold>j</bold> The averaged AMPA/GABA (E/I) ratio is similar between no drug treatment and insulin alone treatment conditions, but application of pioglitazone along with insulin dramatically changed this ratio. <bold>k</bold> Box and whisker plots showing the population distribution</p></caption><graphic id="MO3" xlink:href="13229_2018_196_Fig3_HTML"></graphic></fig></p>
<p id="Par40">We also recorded GABA<sub>A</sub> receptor-mediated sIPSCs in <italic>Met-Emx1</italic> mice. Representative records (Fig. <xref ref-type="fig" rid="Fig4">4</xref>a–c) showed that the amplitudes of sIPSCs increased only during application of insulin plus PIO (Fig. <xref ref-type="fig" rid="Fig4">4</xref>c). The cumulative fraction curves for <italic>Met-Emx1</italic> and <italic>Met-Emx1</italic> I were about the same (Fig. <xref ref-type="fig" rid="Fig4">4</xref>d, thin and medium lines). However, the curve for <italic>Met-Emx1</italic> I + P was shifted to the right, the larger amplitude area (Fig. <xref ref-type="fig" rid="Fig4">4</xref>d, thick line). The averaged amplitude of sIPSCs for <italic>Met-Emx1</italic> mice was 10.10 ± 0.37 pA (<italic>n</italic> = 295, Fig. <xref ref-type="fig" rid="Fig4">4</xref>e, f) that was significantly (<italic>p</italic> &lt; 0.001) smaller than that of WT mice (15.64 ± 0.68 pA). However, application of insulin (<italic>Met</italic> I) did not change (<italic>p</italic> &gt; 0.97) the averaged amplitude of sIPSCs (10.11 ± 0.17 pA, <italic>n</italic> = 470, Fig. <xref ref-type="fig" rid="Fig4">4</xref>e, f), suggesting insulin resistance of GABA<sub>A</sub> receptor-mediated response. Additional PIO together with insulin remarkably (<italic>p</italic> &lt; 0.001) increased the amplitude of sIPSCs to 17.44 ± 0.55 pA (<italic>n</italic> = 235, Fig. <xref ref-type="fig" rid="Fig4">4</xref>e, f) that was still smaller (<italic>p</italic> &lt; 0.001) than WT I + P (20.22 ± 0.56 pA). These suggest that insulin receptors are desensitized in <italic>Met-Emx1</italic> mice. The density of insulin receptors in <italic>Met-Emx1</italic> mice may be lower than that in WT mice.<fig id="Fig4"><label>Fig. 4</label><caption><p>Insulin sensitization-increased inhibition in <italic>Met-EMx1</italic> brain slices<bold>. a</bold>–<bold>c</bold> Example records of GABA<sub>A</sub> receptor-mediated sIPSCs in <italic>Met-EMx1</italic> cortical neurons without drug application, and with insulin alone (I) or insulin + pioglitazone (I + P) applications. <bold>d</bold> Cumulative fraction curves of the sIPSC amplitudes show a significant shift of the amplitude distribution for insulin + pioglitazone condition compared to no drug treatment (<italic>Met-EMx1</italic>) or insulin treatment (<italic>Met-EMx1</italic> I) alone. <bold>e</bold> The average amplitude of sIPSCs is much higher following insulin receptor sensitization with pioglitazone. <bold>f </bold>Box and whisker plots showing the population distribution</p></caption><graphic id="MO4" xlink:href="13229_2018_196_Fig4_HTML"></graphic></fig></p>
</sec>
</sec>
<sec id="Sec13">
<title>Discussion</title>
<p id="Par41">E/I balance in neural circuits is an essential component of homeostatic synaptic plasticity, which is thought to restrain cortical network activity to operate at optimal levels by weakening synaptic efficacy after heightened activity and increasing it after low levels of activation [<xref ref-type="bibr" rid="CR29">29</xref>]. A disturbed E/I balance, particularly in neocortical circuits, has been proposed and observed in ASD individuals and in animal models [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p>
<p id="Par42">In neurodevelopmental disorders, failure in neuronal differentiation [<xref ref-type="bibr" rid="CR32">32</xref>], defects in neurotransmitter release, and their postsynaptic receptors [<xref ref-type="bibr" rid="CR33">33</xref>–<xref ref-type="bibr" rid="CR35">35</xref>] have been linked to altered E/I balance. In neocortical circuits, interactions between Gamma-aminobutyric acidergic (GABAergic) interneurons and glutamatergic pyramidal neurons that form the corticocortical, callosal, and subcortical connections have been targeted by numerous studies seeking to unveil the circuit defects in disorders with cognitive symptoms. GABAergic neurons are a small population of neocortical residents, but they control inhibition of the most populous excitatory cortical neurons. Defects in differentiation of GABAergic interneurons, GABAergic synaptic transmission, and postsynaptic receptors have been the usual suspects in altered excitability and homeostatic plasticity of neural circuits.</p>
<p id="Par43">Met receptor tyrosine kinase is a cell surface receptor activated by hepatocyte growth factor (HGF). For obvious reasons, Met and HGF signaling have been extensively studied in the liver. Met is structurally related to the insulin receptor tyrosine kinase and Met signaling is essential in regulation of insulin response by hepatocytes [<xref ref-type="bibr" rid="CR36">36</xref>]. In fact, a potential therapeutic role for HGF treatment for insulin resistance in type 2 diabetes has been suggested [<xref ref-type="bibr" rid="CR36">36</xref>]. A more recent study on cell cocultures and in knockout mice brings conclusive evidence for Met regulation of insulin sensitivity [<xref ref-type="bibr" rid="CR37">37</xref>]. While both Met and HGF are expressed in a spatiotemporal specificity in the brain (reviewed in [<xref ref-type="bibr" rid="CR1">1</xref>]), there are no studies examining any link between Met signaling and insulin sensitivity in neocortical excitatory neurons and how lack of it might affect GABAergic synaptic transmission.</p>
<p id="Par44">In the primary somatosensory cortex of mice, with inactive autism-associated Met receptor tyrosine kinase, we found that increased excitation is due to decreased postsynaptic inhibition mediated via the GABA<sub>A</sub> receptors [<xref ref-type="bibr" rid="CR6">6</xref>]. Altered GABA<sub>A</sub> receptor function can directly affect the E/I balance. In transgenic mice lacking the β3 subunit of the GABA<sub>A</sub> receptor (Gabrb3), seizure susceptibility, hypersensitivity, hyperactivity, learning, and memory deficits have been reported [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. In fragile X mouse models too, decreased GABA<sub>A</sub> receptor expression has been observed [<xref ref-type="bibr" rid="CR40">40</xref>–<xref ref-type="bibr" rid="CR42">42</xref>]. A potential strategy to ameliorate decreased GABA<sub>A</sub> receptor function is to increase receptor sensitivity. In cultured hippocampal neuron, application of insulin increased GABA<sub>A</sub> receptor-mediated response [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. We confirmed this response in thalamocortical slices taken from WT mice [<xref ref-type="bibr" rid="CR6">6</xref>]. However, in thalamocortical slices from <italic>Met-Emx1</italic> mice, insulin application did not change GABA<sub>A</sub> receptor-mediated response, suggesting that there might be insulin resistance in neocortical neurons that lack Met function [<xref ref-type="bibr" rid="CR6">6</xref>]. In the present study, we show that insulin resistance of GABA<sub>A</sub> receptor-mediated response in <italic>Met-Emx1</italic> mice can be altered by insulin sensitization. We find that application of PIO, a common insulin sensitizer used in diabetes therapy, can significantly alter the GABA<sub>A</sub> receptor response and restore E/I balance to levels of normalcy. At the present time, we do not know how Met deficiency in excitatory cortical neurons alters receptor desensitization or the intracellular signaling pathways involving insulin receptors. Further studies are needed to investigate these mechanisms in a cell type-specific manner to determine whether Met signaling through insulin receptors occurs in similar ways between the neocortical excitatory neurons and hepatocytes.</p>
</sec>
<sec id="Sec14">
<title>Conclusions</title>
<p id="Par45">Excitation/inhibition balance is altered in favor of excitation in the primary somatosensory cortex of mice with inactive autism-associated Met receptor tyrosine kinase. Altered E/I balance, in favor of excitation, in the somatosensory cortex of mice with inactive autism-associated Met receptor tyrosine kinase may relate to somatic sensory hypersensitivity of children with ASD to shoes and clothing. We applied insulin alone and insulin + pioglitazone (PIO) to test the effects of sensitizing insulin receptors on inhibitory responses mediated by GABA<sub>A</sub> receptors in the thalamocortical circuitry of <italic>Emx1</italic><sup><italic>cre</italic></sup><italic>/Met</italic>
<sup><italic>flox</italic></sup> mice. We show that PIO can aid in normalization of the E/I balance in the primary somatosensory cortex, a potential physiological mechanism underlying the positive effects of PIO treatment in ASD patients. Our results shed light to the underlying mechanisms and suggest that decreased GABA<sub>A</sub> receptor activity is the major culprit in scaling E/I balance to more excitation and that insulin sensitization can help in readjusting the balance.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>ACSF</term>
<def>
<p id="Par5">Artificial cerebrospinal fluid</p>
</def>
</def-item>
<def-item>
<term>AMPA</term>
<def>
<p id="Par6">α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid</p>
</def>
</def-item>
<def-item>
<term>ASD</term>
<def>
<p id="Par7">Autism spectrum disorder</p>
</def>
</def-item>
<def-item>
<term>C57BL/6</term>
<def>
<p id="Par8">Most widely used inbred mouse strain</p>
</def>
</def-item>
<def-item>
<term>DL-APV</term>
<def>
<p id="Par9">DL-2-Amino-5-phosphonopentanoic acid</p>
</def>
</def-item>
<def-item>
<term>E/I</term>
<def>
<p id="Par10">Excitation/inhibition</p>
</def>
</def-item>
<def-item>
<term>Emx1</term>
<def>
<p id="Par11">Empty spiracles homeobox</p>
</def>
</def-item>
<def-item>
<term>EPSC</term>
<def>
<p id="Par12">Excitatory postsynaptic current</p>
</def>
</def-item>
<def-item>
<term>GABA<sub>A</sub></term>
<def>
<p id="Par13">Ionotropic receptor and γ-aminobutyric acid-gated ion channel</p>
</def>
</def-item>
<def-item>
<term>Gabrb3</term>
<def>
<p id="Par14">β3 subunit of the GABA<sub>A</sub> receptor</p>
</def>
</def-item>
<def-item>
<term>HGF</term>
<def>
<p id="Par15">Hepatocyte growth factor</p>
</def>
</def-item>
<def-item>
<term>I + P</term>
<def>
<p id="Par16">Insulin + pioglitazone</p>
</def>
</def-item>
<def-item>
<term>I</term>
<def>
<p id="Par17">Insulin</p>
</def>
</def-item>
<def-item>
<term>IPSC</term>
<def>
<p id="Par18">Inhibitory postsynaptic current</p>
</def>
</def-item>
<def-item>
<term>Met</term>
<def>
<p id="Par19">Tyrosine-protein kinase Met or hepatocyte growth factor receptor</p>
</def>
</def-item>
<def-item>
<term>NBQX</term>
<def>
<p id="Par20">2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F) quinoxaline, potent AMPA receptor antagonist</p>
</def>
</def-item>
<def-item>
<term>NMDA</term>
<def>
<p id="Par21"><italic>N</italic>-methyl-<sc>d</sc>-aspartate</p>
</def>
</def-item>
<def-item>
<term>PIO</term>
<def>
<p id="Par22">Pioglitazone</p>
</def>
</def-item>
<def-item>
<term>PTX</term>
<def>
<p id="Par23">Picrotoxin</p>
</def>
</def-item>
<def-item>
<term>sIPSC</term>
<def>
<p id="Par24">Spontaneous inhibitory synaptic current</p>
</def>
</def-item>
<def-item>
<term>VB</term>
<def>
<p id="Par25">Ventrobasal nucleus of thalamus</p>
</def>
</def-item>
<def-item>
<term>WT</term>
<def>
<p id="Par26">Wild type (B6 mice)</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgements</title>
<p>We thank Dr. Elizabeth Powell for introducing us to the autism model mice and discussions on the cortical phenotypes of the <italic>Met</italic> mutant mice.</p>
<sec id="FPar1">
<title>Funding</title>
<p id="Par46">Research supported by NIH/NINDS R01 NS092216</p>
</sec>
<sec id="FPar2">
<title>Availability of data and materials</title>
<p id="Par47">The mice used in this study are commercially available. Electrophysiological data are available from the corresponding author on reasonable request.</p>
</sec>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>FSL and RSE designed the study. FSL performed the experiments. FSL and RSE interpreted the results and wrote the manuscript. Both authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar3">
<title>Ethics approval</title>
<p id="Par48">All protocols strictly conformed to the National Institute of Health Guide for the Care and Use of Laboratory Animals (ISBN:13:978-0-309-15400-0, revised in 2011) and were approved by the University of Maryland Baltimore Institutional Animal Care and Use Committee.</p>
</sec>
<sec id="FPar4">
<title>Consent for publication</title>
<p id="Par49">Not applicable</p>
</sec>
<sec id="FPar5">
<title>Competing interests</title>
<p id="Par50">The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar6">
<title>Publisher’s Note</title>
<p id="Par51">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eagleson</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The pleiotropic MET receptor network: circuit development and the neural-medical interface of autism</article-title>
<source/>Biol Psychiatry
          <year>2017</year>
<volume>81</volume>
<fpage>424</fpage>
<lpage>433</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2016.08.035</pub-id>
<pub-id pub-id-type="pmid">27837921</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Piechowicz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Uddin</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The autism-associated MET receptor tyrosine kinase engages early neuronal growth mechanism and controls glutamatergic circuits development in the forebrain</article-title>
<source/>Mol Psychiatry
          <year>2016</year>
<volume>21</volume>
<fpage>925</fpage>
<lpage>935</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2015.182</pub-id>
<pub-id pub-id-type="pmid">26728565</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eagleson</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Coba</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Receptor tyrosine kinase MET interactome and neurodevelopmental disorder partners at the developing synapse</article-title>
<source/>Biol Psychiatry
          <year>2016</year>
<volume>80</volume>
<fpage>933</fpage>
<lpage>942</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2016.02.022</pub-id>
<pub-id pub-id-type="pmid">27086544</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Judson</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Bergman</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Eagleson</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Dynamic gene and protein expression patterns of the autism-associated met receptor tyrosine kinase in the developing mouse forebrain</article-title>
<source/>J Comp Neurol
          <year>2009</year>
<volume>513</volume>
<fpage>511</fpage>
<lpage>531</lpage>
<pub-id pub-id-type="doi">10.1002/cne.21969</pub-id>
<pub-id pub-id-type="pmid">19226509</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qui</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>GM</given-names>
</name>
</person-group>
<article-title>Circuit-specific intracortical hyperconnectivity in mice with deletion of the autism-associated met receptor tyrosine kinase</article-title>
<source/>J Neurosci
          <year>2011</year>
<volume>31</volume>
<fpage>5855</fpage>
<lpage>5864</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.6569-10.2011</pub-id>
<pub-id pub-id-type="pmid">21490227</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Erzurumlu</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Powell</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Insulin-independent GABAA receptor-mediated response in the barrel cortex of mice with impaired met activity</article-title>
<source/>J Neurosci
          <year>2016</year>
<volume>36</volume>
<fpage>3691</fpage>
<lpage>3697</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0006-16.2016</pub-id>
<pub-id pub-id-type="pmid">27030755</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelson</surname>
<given-names>SB</given-names>
</name>
<name>
<surname>Valakh</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Excitatory/inhibitory balance and circuit homeostasis in autism spectrum disorders</article-title>
<source/>Neuron
          <year>2015</year>
<volume>87</volume>
<fpage>684</fpage>
<lpage>698</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2015.07.033</pub-id>
<pub-id pub-id-type="pmid">26291155</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Haley</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Tselha</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Maffei</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Neurophysiology and regulation of the balance between excitation and inhibition in neocortical circuits</article-title>
<source/>Biol Psychiatry
          <year>2016</year>
<volume>81</volume>
<fpage>821</fpage>
<lpage>831</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2016.09.017</pub-id>
<pub-id pub-id-type="pmid">27865453</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gralle</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The neuronal insulin receptor in its environment</article-title>
<source/>J Neurochem
          <year>2017</year>
<volume>140</volume>
<fpage>359</fpage>
<lpage>367</lpage>
<pub-id pub-id-type="doi">10.1111/jnc.13909</pub-id>
<pub-id pub-id-type="pmid">27889917</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Werne</surname>
<given-names>H</given-names>
</name>
<name>
<surname>LeRoith</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Insulin and insulin-like growth factor receptors in the brain: physiological and pathological aspects</article-title>
<source/>Eur Neuropsychopharmacol
          <year>2014</year>
<volume>24</volume>
<fpage>1947</fpage>
<lpage>1953</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.01.020</pub-id>
<pub-id pub-id-type="pmid">24529663</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vetiska</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Ahmadian</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ju</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wymann</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YT</given-names>
</name>
</person-group>
<article-title>GABAA receptor-associated phosphoinositide 3-kinase is required for insulin-induced recruitment of postsynaptic GABAA receptors</article-title>
<source/>Neuropharmacology
          <year>2007</year>
<volume>52</volume>
<fpage>146</fpage>
<lpage>155</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2006.06.023</pub-id>
<pub-id pub-id-type="pmid">16890252</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Accardi</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Miraucourt</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Orser</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Bowie</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>α6-containing GABAA receptors are the principal mediators of inhibitory synapse strengthening by insulin in cerebellar granule cells</article-title>
<source/>J Neurosci
          <year>2015</year>
<volume>35</volume>
<fpage>9676</fpage>
<lpage>9688</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.0513-15.2015</pub-id>
<pub-id pub-id-type="pmid">26134650</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawaguchi-Suzuki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Frye</surname>
<given-names>RF</given-names>
</name>
</person-group>
<article-title>Current clinical evidence on pioglitazone pharmacogenomics</article-title>
<source/>Front Pharmacol
          <year>2013</year>
<volume>4</volume>
<fpage>147</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2013.00147</pub-id>
<pub-id pub-id-type="pmid">24324437</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boris</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kaiser</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Goldblatt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Elice</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Edelson</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Feinstein</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>Effect of pioglitazone treatment on behavioral symptoms in autistic children</article-title>
<source/>J Neuroinflammation
          <year>2007</year>
<volume>4</volume>
<fpage>3</fpage>
<pub-id pub-id-type="doi">10.1186/1742-2094-4-3</pub-id>
<pub-id pub-id-type="pmid">17207275</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emanuele</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lossano</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Politi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Barale</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Pioglitazone as a therapeutic agent in autistic spectrum disorder</article-title>
<source/>Med Hypotheses
          <year>2007</year>
<volume>69</volume>
<fpage>699</fpage>
<pub-id pub-id-type="doi">10.1016/j.mehy.2007.01.018</pub-id>
<pub-id pub-id-type="pmid">17335984</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doyle</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>McDougle</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Pharmacotherapy to control behavioral symptoms in children with autism</article-title>
<source/>Expert Opin Pharmacother
          <year>2012</year>
<volume>13</volume>
<fpage>1615</fpage>
<lpage>1629</lpage>
<pub-id pub-id-type="doi">10.1517/14656566.2012.674110</pub-id>
<pub-id pub-id-type="pmid">22550944</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Read</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Biscow</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Sustained 4-year cognitive and functional response in early Alzheimer’s disease with pioglitazone</article-title>
<source/>J Am Geriatr Soc
          <year>2014</year>
<volume>62</volume>
<fpage>584</fpage>
<lpage>586</lpage>
<pub-id pub-id-type="doi">10.1111/jgs.12722</pub-id>
<pub-id pub-id-type="pmid">24628640</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghaleiha</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rasa</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Nikoo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Farokhnia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mohammadi</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Akhondzadeh</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism</article-title>
<source/>Psychiatry Res
          <year>2015</year>
<volume>229</volume>
<fpage>181</fpage>
<lpage>187</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2015.07.043</pub-id>
<pub-id pub-id-type="pmid">26208985</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galimberti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Scarpini</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Pioglitazone for the treatment of Alzheimer’s disease</article-title>
<source/>Expert Opin Investig Drugs
          <year>2017</year>
<volume>26</volume>
<fpage>97</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1080/13543784.2017.1265504</pub-id>
<pub-id pub-id-type="pmid">27885860</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>GA</given-names>
</name>
</person-group>
<article-title>Primary and secondary prevention trials in Alzheimer’s disease looking back, moving forward</article-title>
<source/>Curr Allzheimer Re
          <year>2017</year>
<volume>14</volume>
<fpage>426</fpage>
<lpage>440</lpage>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agmon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Connors</surname>
<given-names>BW</given-names>
</name>
</person-group>
<article-title>Thalamocortical responses of mouse somatosensory (barrel) cortex in vitro</article-title>
<source/>Neuroscience
          <year>1991</year>
<volume>41</volume>
<fpage>365</fpage>
<lpage>379</lpage>
<pub-id pub-id-type="doi">10.1016/0306-4522(91)90333-J</pub-id>
<pub-id pub-id-type="pmid">1870696</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Iwasato</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Itohara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Erzurumlu</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Exuberant thalamocortical axon arborization in cortex-specific NMDAR1 knockout mice</article-title>
<source/>J Comp Neurol
          <year>2005</year>
<volume>485</volume>
<fpage>280</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="doi">10.1002/cne.20481</pub-id>
<pub-id pub-id-type="pmid">15803506</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Synaptic properties of thalamic and intracortical inputs to layer 4 of the first- and higher-order cortical areas in the auditory and somatosensory systems</article-title>
<source/>J Neurophysiol
          <year>2008</year>
<volume>100</volume>
<fpage>317</fpage>
<lpage>326</lpage>
<pub-id pub-id-type="doi">10.1152/jn.90391.2008</pub-id>
<pub-id pub-id-type="pmid">18436628</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agmon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Connors</surname>
<given-names>BW</given-names>
</name>
</person-group>
<article-title>Correlation between intrinsic firing patterns and thalamocortical synaptic responses of neurons in mouse barrel cortex</article-title>
<source/>J Neurosci
          <year>1992</year>
<volume>12</volume>
<fpage>319</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="pmid">1729440</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldmeyer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Egger</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lubke</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sakmann</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Reliable synaptic connections between pairs of excitatory layer 4 neurones within a single ‘barrel’ of developing rat somatosensory cortex</article-title>
<source/>J Physiol
          <year>1999</year>
<volume>521</volume>
<issue>Pt 1</issue>
<fpage>169</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-7793.1999.00169.x</pub-id>
<pub-id pub-id-type="pmid">10562343</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beierlein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Connors</surname>
<given-names>BW</given-names>
</name>
</person-group>
<article-title>Two dynamically distinct inhibitory networks in layer 4 of the neocortex</article-title>
<source/>J Neurophysiol
          <year>2003</year>
<volume>90</volume>
<fpage>2987</fpage>
<lpage>3000</lpage>
<pub-id pub-id-type="doi">10.1152/jn.00283.2003</pub-id>
<pub-id pub-id-type="pmid">12815025</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Akkentli</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tsytsarev</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Erzurumlu</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Functional significance of cortical NMDA receptors in somatosensory information processing</article-title>
<source/>J Neurophysiol
          <year>2013</year>
<volume>110</volume>
<fpage>2627</fpage>
<lpage>2636</lpage>
<pub-id pub-id-type="doi">10.1152/jn.00052.2013</pub-id>
<pub-id pub-id-type="pmid">24047907</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Blue</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Erzurumlu</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>Enhancement of postsynaptic GABAA and extrasynaptic NMDA receptor-mediated responses in the barrel cortex of Mecp2-null mice</article-title>
<source/>J Neurophysiol
          <year>2016</year>
<volume>115</volume>
<fpage>1298</fpage>
<lpage>1306</lpage>
<pub-id pub-id-type="doi">10.1152/jn.00944.2015</pub-id>
<pub-id pub-id-type="pmid">26683074</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turrigiano</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Homeostatic synaptic plasticity: local and global mechanisms for stabilizing neuronal function</article-title>
<source/>Cold Spring Harb Perspect Biol
          <year>2012</year>
<volume>4</volume>
<issue>1</issue>
<fpage>a005736</fpage>
<pub-id pub-id-type="doi">10.1101/cshperspect.a005736</pub-id>
<pub-id pub-id-type="pmid">22086977</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubenstein</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Merzenich</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Model of autism: increased ratio of excitation/inhibition in key neural systems</article-title>
<source/>Genes Brain Behav
          <year>2003</year>
<volume>2</volume>
<fpage>255</fpage>
<lpage>267</lpage>
<pub-id pub-id-type="doi">10.1034/j.1601-183X.2003.00037.x</pub-id>
<pub-id pub-id-type="pmid">14606691</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gogolla</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Leblanc</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Quast</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Südhof</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Fagiolini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hensch</surname>
<given-names>TK</given-names>
</name>
</person-group>
<article-title>Common circuit defect of excitatory-inhibitory balance in mouse models of autism</article-title>
<source/>J Neurodev Disord
          <year>2009</year>
<volume>1</volume>
<fpage>172</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1007/s11689-009-9023-x</pub-id>
<pub-id pub-id-type="pmid">20664807</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mihalas</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Hevner</surname>
<given-names>RF</given-names>
</name>
</person-group>
<article-title>Control of neuronal development by T-box genes in the brain</article-title>
<source/>Curr Top Dev Biol
          <year>2017</year>
<volume>122</volume>
<fpage>279</fpage>
<lpage>312</lpage>
<pub-id pub-id-type="doi">10.1016/bs.ctdb.2016.08.001</pub-id>
<pub-id pub-id-type="pmid">28057268</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tong</surname>
<given-names>XJ</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kaplan</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>A network of autism linked genes stabilizes two pools of synaptic GABA(a) receptors</article-title>
<source/>elife
          <year>2015</year>
<volume>4</volume>
<fpage>e09648</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.09648</pub-id>
<pub-id pub-id-type="pmid">26575289</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Thevathasan</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Kuroda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kaibuchi</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Stimulation of synaptic vesicle exocytosis by the mental disease gene DISC1 is mediated by N-type voltage-gated calcium channels</article-title>
<source/>Front Synaptic Neurosci
          <year>2016</year>
<volume>8</volume>
<fpage>15</fpage>
<pub-id pub-id-type="doi">10.3389/fnsyn.2016.00015</pub-id>
<pub-id pub-id-type="pmid">27378904</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fafalios</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Stoops</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>DeFrances</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Zarnegar</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>A hepatocyte growth factor receptor (met)-insulin receptor hybrid governs hepatic glucose mechanism</article-title>
<source/>Nat Med
          <year>2011</year>
<volume>17</volume>
<fpage>1577</fpage>
<lpage>1584</lpage>
<pub-id pub-id-type="doi">10.1038/nm.2531</pub-id>
<pub-id pub-id-type="pmid">22081023</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y-Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>G-F</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>L-J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Deletion of macrophage mineralocorticoid receptor protects hepatic steatosis and insulin resistance through Erα/HGF/met pathway</article-title>
<source/>Diabetes
          <year>2017</year>
<volume>66</volume>
<fpage>1535</fpage>
<lpage>1547</lpage>
<pub-id pub-id-type="doi">10.2337/db16-1354</pub-id>
<pub-id pub-id-type="pmid">28325853</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Q</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced glutamate release in adult BTBR mouse model of autism spectrum disorder</article-title>
<source/>Neurochem Res
          <year>2016</year>
<volume>41</volume>
<fpage>3129</fpage>
<lpage>3137</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-016-2035-5</pub-id>
<pub-id pub-id-type="pmid">27538958</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeLorey</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Handforth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Anagnostaras</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Homanics</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Minassianm</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Asatourian</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome</article-title>
<source/>J Neurosci
          <year>1998</year>
<volume>18</volume>
<fpage>8505</fpage>
<lpage>8514</lpage>
<pub-id pub-id-type="pmid">9763493</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Homanics</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>DeLorey</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Firestone</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Quinlan</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Handforth</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>NL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mice devoid of gamma-aminobutyrate type a receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1997</year>
<volume>94</volume>
<fpage>4143</fpage>
<lpage>4148</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.94.8.4143</pub-id>
<pub-id pub-id-type="pmid">9108119</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Idrissi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Scalia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Trenkner</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Dobkin</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Decreased GABA(a) receptor expression in the seizure-prone fragile X mouse</article-title>
<source/>Neurosci Lett
          <year>2005</year>
<volume>377</volume>
<fpage>141</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2004.11.087</pub-id>
<pub-id pub-id-type="pmid">15755515</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gantois</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Vandesompele</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Speleman</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Reyniers</surname>
<given-names>E</given-names>
</name>
<name>
<surname>D’Hooge</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Severijnen</surname>
<given-names>LA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expression profiling suggests underexpression of the GABA(a) receptor subunit delta in the fragile X knockout mouse model</article-title>
<source/>Neurobiol Dis
          <year>2006</year>
<volume>21</volume>
<fpage>346</fpage>
<lpage>357</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2005.07.017</pub-id>
<pub-id pub-id-type="pmid">16199166</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adusei</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Pacey</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hampson</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>Early developmental alterations in GABAergic protein expression in fragile X knockout mice</article-title>
<source/>Neuropharmacology
          <year>2010</year>
<volume>59</volume>
<fpage>167</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2010.05.002</pub-id>
<pub-id pub-id-type="pmid">20470805</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wan</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>ZG</given-names>
</name>
<name>
<surname>Man</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Ackerley</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Braunton</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Recruitment of functional GABA(a) receptors to postsynaptic domains by insulin</article-title>
<source/>Nature
          <year>1997</year>
<volume>388</volume>
<fpage>686</fpage>
<lpage>690</lpage>
<pub-id pub-id-type="doi">10.1038/41792</pub-id>
<pub-id pub-id-type="pmid">9262404</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mielke</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>YT</given-names>
</name>
</person-group>
<article-title>Insulin exerts neuroprotection by counteracting the decrease in cell-surface GABA receptors following oxygen-glucose deprivation in cultured cortical neurons</article-title>
<source/>J Neurochem
          <year>2005</year>
<volume>92</volume>
<fpage>103</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02841.x</pub-id>
<pub-id pub-id-type="pmid">15606900</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>